Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266

Watchlist Manager
Suzhou Zelgen Biopharmaceuticals Co Ltd Logo
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Watchlist
Price: 65.4 CNY -1.06%
Market Cap: 17.3B CNY

Wall Street
Price Targets

Price Targets Summary
Suzhou Zelgen Biopharmaceuticals Co Ltd

There are no price targets for Suzhou Zelgen Biopharmaceuticals Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors:
Price Targets
COYA
Coya Therapeutics Inc
179% Upside
TNGX
Tango Therapeutics Inc
281% Upside
AGIO
Agios Pharmaceuticals Inc
79% Upside
MDGL
Madrigal Pharmaceuticals Inc
17% Upside
CYTK
Cytokinetics Inc
81% Upside
002675
Yantai Dongcheng Biochemicals Co Ltd
34% Upside
EXAS
Exact Sciences Corp
36% Upside
688105
Nanjing Vazyme Biotech Co Ltd
26% Upside

Revenue
Forecast

Revenue Estimate
Suzhou Zelgen Biopharmaceuticals Co Ltd

The compound annual growth rate of Suzhou Zelgen Biopharmaceuticals Co Ltd's revenue for the next 3 years is 68%.

N/A
Past Growth
68%
Estimated Growth
Estimates Accuracy
-13%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Suzhou Zelgen Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
9%
Average Beat

Net Income
Forecast

Net Income Estimate
Suzhou Zelgen Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's stock price target?
Not Available

Suzhou Zelgen Biopharmaceuticals Co Ltd doesn't have any price targets made by Wall Street professionals.

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
68%

The compound annual growth rate of Suzhou Zelgen Biopharmaceuticals Co Ltd's revenue for the next 3 years is 68%.

Back to Top